Trial Profile
An Interferon Sparing Strategy of Sofosbuvir Plus Ribavirin for the Treatment of Recently Acquired Hepatitis C Infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms DARE-C II
- 19 Sep 2018 Status changed from active, no longer recruiting to completed.
- 19 Oct 2016 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
- 17 Sep 2016 Results published in the Hepatology